


Optic nerve glioma: an update

**Akshay Gopinathan Nair, Rima
S. Pathak, Veena R. Iyer & Rashmin
A. Gandhi**

International Ophthalmology
The International Journal of Clinical
Ophthalmology and Visual Sciences

ISSN 0165-5701
Volume 34
Number 4

Int Ophthalmol (2014) 34:999-1005
DOI 10.1007/s10792-014-9942-8



Your article is protected by copyright and all rights are held exclusively by Springer Science +Business Media Dordrecht. This e-offprint is for personal use only and shall not be self-archived in electronic repositories. If you wish to self-archive your article, please use the accepted manuscript version for posting on your own website. You may further deposit the accepted manuscript version in any repository, provided it is only made publicly available 12 months after official publication or later and provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com".

Optic nerve glioma: an update

Akshay Gopinathan Nair · Rima S. Pathak ·
Veena R. Iyer · Rashmin A. Gandhi

Received: 17 February 2014 / Accepted: 30 March 2014 / Published online: 16 April 2014
© Springer Science+Business Media Dordrecht 2014

Abstract Optic nerve glioma is the most common optic nerve tumour. However, it has an unpredictable natural history. The treatment of optic nerve gliomas has changed considerably over the past few years. Chemotherapy and radiation therapy can now stabilize and in some cases improve the vision of patients with optic nerve gliomas. The treatment of optic nerve glioma requires a multi-disciplinary approach where all treatment options may have to be implemented in a highly individualized manner. The aim of this review article is to present current diagnostic and treatment protocols for optic nerve glioma.

Keywords Optic nerve glioma · Proptosis · Neurofibromatosis · Tumour

Introduction

Optic nerve gliomas are the most common tumours of the optic nerve. Optic nerve tumours are classified as

A. G. Nair (✉) · R. A. Gandhi
Department of Neuro-Ophthalmology, Sankara
Nethralaya, A Unit of Medical Research Foundation, 18
College Road, Nungambakkam, Chennai 600 006, India
e-mail: akshaygn@gmail.com

R. S. Pathak
Department of Radiation Oncology, Tata Memorial
Hospital, Parel, Mumbai, India

V. R. Iyer
Department of Diagnostic Radiology, University of
Minnesota, Minneapolis, MN, USA

either those arising from the optic nerve matter or those arising from the surrounding sheath. These tumours are difficult to treat and manage owing to the high risk of damage to the optic nerve itself. More than 90 % of primary optic nerve tumours are either benign gliomas of childhood or optic nerve sheath meningiomas [1]. Optic nerve gliomas comprise about 1 % of all intracranial tumours [2].

Optic nerve gliomas are of two different types— one being the juvenile benign pilocytic astrocytoma and the other being the malignant glioblastoma of adulthood.

Benign optic nerve glioma

These benign tumours usually present in the first decade of life. They are almost always unilateral and occur more frequently in females. While the incidence may be sporadic or sometimes familial, most of the patients presenting with optic nerve gliomas have neurofibromatosis type 1 (NF-1). Reports have shown varying levels of incidence of NF-1 among patients of optic nerve glioma: 10–70 %, whereas the incidence of optic nerve glioma in patients with NF-1 varies from 8 to 31 % [3, 4].

Clinical features

Proptosis is usually gradual, painless and often associated with infradisplacement of the globe.

However, on rare occasions, a patient may present with acute loss of vision. This is associated with development or worsening of proptosis, which results from haemorrhage into the tumour [5]. Optic disc swelling or pallor, visual acuity loss, visual field loss and relative afferent pupillary defect are seen due to compressive effects of the tumour. The tumour eventually causes optic nerve atrophy because of pressure effects on the nerve fibres as well as the nutrient arteries. Primary and secondary strabismus is seen, along with restriction of extra ocular muscle motility. Also, dissociated vertical nystagmus may be seen in suprasellar extending lesions [1]. Chronic compression of the central retinal vein can cause central retinal vein occlusion (CRVO). As a result, venous stasis retinopathy, optociliary shunt vessels are seen. Furthermore this may lead to rubeosis irides and even neovascular glaucoma [3]. Chiasmatic gliomas may present with slow bilateral visual loss associated with bitemporal field defects, optic disc changes and strabismus [6]. Endocrinal disturbances may also be seen in patients with chiasmatic gliomas. Sporadic optic nerve glioma more often present with symptoms of raised intracranial pressure owing to their spread beyond the chiasm; in contrast to the tumours associated with NF-1 in whom precocious puberty is more commonly seen [7–9].

Diagnosis

Gliomas that are limited to only one optic nerve do not cause bilateral blindness and are not life threatening. The prognosis for life and vision worsens once the optic chiasm is involved [10]. Optic nerve gliomas can involve both, the chiasm and one or both optic nerves, and half of those extending to the chiasm also involve the hypothalamus [11]. Therefore, early diagnosis and management are of importance in these cases. Given the association of NF-1 with optic nerve gliomas, there are well-defined recommended guidelines for the management and diagnosis of NF-1 associated gliomas [7]. They state that all children with NF-1 younger than 8 years of age should undergo a thorough annual ophthalmological examination but baseline 'screening' neuroimaging or visual evoked potentials of asymptomatic children with normal visual examinations is not warranted. The optimal frequency of ophthalmological assessment for children older than 8 years is not known. The current recommendation is



Fig. 1 Optic nerve glioma in a 3-year-old girl with left proptosis. Axial noncontrast CT image shows an isodense lobulated intraconal mass along the left optic nerve that causes left proptosis


that eye examinations be performed every 2 years until 18 years of age. No particular screening for optic nerve gliomas in adults with NF-1 is recommended [6, 7].

Radiological findings

On CT, the tumour appears as an iso- to hypoattenuating fusiform enlargement of the optic nerve, sometimes with kinking or tortuosity of its course (Fig. 1). Less commonly, it is an eccentric or discrete mass arising from the nerve [12]. CT can also reveal subtle erosions and enlargement of the optic canal and the rare fine calcifications [13]. Although intrinsic contrast with intraconal fat on CT allows for evaluation of the optic nerve, MR imaging is the modality of choice to evaluate intracranial extent, including extension to the optic chiasm, hypothalamus and beyond.

MR imaging protocols using coronal and axial thin-section T1-weighted and fat-saturated T2-weighted images are useful [14], as is additional evaluation with paramagnetic contrast agents. The size and course of the nerve are best evaluated on T1-weighted images without fat saturation [12] (Fig. 2a). The tumour is iso- to hypointense to the optic pathway on T1-weighted images and slightly hyperintense on T2-weighted images, with rare areas of haemorrhage and calcification. Variable patterns of enhancement are seen with intravenous gadolinium. Two architectural

Fig. 2 Optic nerve glioma in a 4-year-old boy with right proptosis and headache. **a** Axial unenhanced T1-weighted image shows a fusiform, isointense mass along the right optic nerve. The normal hyperintense intraconal fat provides intrinsic contrast to delineate the mass. **b** Postcontrast fat-suppressed T1-weighted axial image at the same level shows intense enhancement in the mass



patterns are evident with contrast. In the diffuse type, which grows predominantly within the optic nerve parenchyma, the nerve is enlarged and the surrounding subarachnoid space is effaced (Fig. 2b). In the other form, enhancing tumour in the subarachnoid space compresses the normal-sized minimally enhancing nerve [12]. Cystic tumours show enhancement of the wall of the cyst. Enhancement in optic nerve gliomas is associated with a more aggressive behaviour [13]. Extension of the tumour into the intracanalicular and retrocanalicular portions of the optic nerve seen only with postcontrast imaging has important management implications. Extension to the chiasm through the optic canal produces a characteristic dumbbell-shaped configuration. Large tumours in the suprasellar area may simulate other suprasellar tumours, but involvement of intraorbital optic nerves helps differentiate from other suprasellar masses [15]. Rarely, the tumour may extend into the lateral geniculate bodies and optic radiations [12].

Some imaging findings of optic pathway tumours differ between children with and without neurofibromatosis. Bilateral optic nerve tumours are pathognomonic for NF-1. Tumours isolated to the optic nerve are more commonly seen in patients with NF-1, while intracranial extension is more common without NF-1 [12]. The tumour causes nerve enlargement without altering its configuration in most patients with NF-1 but in only a small minority without NF-1. Tumour diameter and volumes tend to be greater in non-NF-1 cases. Cystic components are rare in NF-1. Hydrocephalus is almost exclusively seen in non-NF-1 cases [12]. Dural ectasia seen in NF-1 should not be


confused with involvement of the subarachnoid space by tumour. In dural ectasia, the enlarged subarachnoid space follows the signal intensity of CSF and does not enhance [14] (Fig. 3).

Treatment

As discussed earlier, optic nerve gliomas may sometime involve the chiasm and cause visual symptoms in the contralateral eye as well. This occurrence, however, is rare [3]. The treatment of optic nerve gliomas, consisting of a multi-disciplinary approach with fractionated stereotactic radiotherapy (FSRT), is now emerging as one of the preferred treatment modalities.

1. *Observation* The natural history of childhood optic nerve gliomas is almost always benign and most tumours grow slowly in a self-limited manner and some even spontaneously regress. Some long-term studies indicate that patients who are not treated may retain stable visual function [3]. It has been recommended that most patients with unilateral optic nerve gliomas, particularly those with NF-1, be followed at regular intervals both clinically and with neuroimaging without intervention unless there is documented visual deterioration. Once visual deterioration occurs, treatment may be considered.
2. *Chemotherapy* The optimal role of chemotherapy in paediatric optic nerve glioma has not been determined. Chemotherapy holds the possibility of delaying or entirely avoiding the implementation of therapies that have potentially greater

Fig. 3 **a** Postcontrast fat-suppressed T1-weighted sagittal image shows that the mass is confined to the orbit, without extension into the chiasm. **b** Postcontrast fat-suppressed T1-weighted coronal image again shows the enhancing right optic glioma and the normal nonenhancing left optic nerve



long-term toxicities (i.e. radiotherapy and surgery) [16]. This is particularly important for the youngest patients, and reports have suggested that chemotherapy should be the primary treatment modality for ONG in children under age 3 years [17]. Chemotherapy was first studied in 1977 (Vincristine with Actinomycin D) and was found to be effective. Numerous studies have been published since then addressing the chemotherapeutic management of low-grade gliomas as a whole. Packer and colleagues [18, 19] were one of the first to evaluate concurrent carboplatin and vincristine chemotherapy in patients with newly diagnosed progressive disease and patients with recurrent disease. A 10-week induction phase, followed by 48 weeks of maintenance carboplatin/vincristine was used resulting in a progression-free survival (PFS) of 75 % at 2 years and 68 % at 3 years. Children aged 5 years or younger had a notably more favourable overall rate of response. This is presently the most commonly used regimen for low-grade gliomas. On comparing toxicity of TPCV (6-thioguanine, procarbazine, CCNU and vincristine) with the Packer regimen (carboplatin/vincristine), another study concluded that TPCV had bone marrow toxicity comparable to that of carboplatin/vincristine, and found it suitable for second-line therapy [20]. A vast majority of children experience disease progression and require salvage therapy, most commonly including radiation therapy. Risks

associated with chemotherapy are also substantial like renal toxicity, myelosuppression, peripheral neuropathy, ototoxicity, etc. These toxicities are difficult to recognize in very young patients, and hence strict monitoring with thorough evaluation at regular interval during and after treatment is prudent. Newer targeted therapies are being studied for their use in young children with optic pathway gliomas including bevacizumab and temozolomide but none have shown dramatically better results compared to the standard chemotherapy regimen even in phase II studies.

3. **Radiotherapy** Radiotherapy has been used for a long time for treatment of optic pathway gliomas [21–23]. There are many single institution studies reported in literature that indicate that patients with optic nerve glioma treated with radiotherapy have 10-year PFS of approximately 80 %. About a third of patients experience objective improvement in vision, and approximately half of them show some sign of tumour regression on imaging. [24–27].

Treating young patients with ionizing radiation poses a challenge. If patients are treated with conventional portals, then a large part of developing brain, contralateral orbit, pituitary, internal ear and other vital structures receive high doses of radiation which increases morbidity and hampers the quality of life. Also since these patients have a long-term survival, there is a higher probability of developing a second malignancy. Various

investigators have used a wide variety of doses but majority of them range from 45 to 58 Gy. As a standard, most institutes now use 3D conformal radiotherapy to a dose of 45–50.4 Gy in conventional fractionation. Radiotherapy can also be delivered in daily fractions to treat larger tumours—this ensures that the surrounding tissues benefit from normal tissue sparing properties of fractionated radiotherapy. FSRT combines the target and dose localization characteristics of stereotactic radiosurgery with the obvious advantages of fractionation [18]. It has been seen that radiotherapy is effective in achieving functional improvement and stabilizing disease even with conventional techniques [22]. In a retrospective analysis, Dororetz et al. [23] reported that early radiotherapy had a positive influence on PFS. Combs et al. [30], while evaluating the tolerance and long-term outcome of FSRT of optic pathway gliomas, have reported that FSRT was safe and well tolerated in all patients. FSRT was delivered to a total dose of 52.2 Gy in 29 fractions at 1.8 Gy/fraction. In their study of 15 patients with optic gliomas, the PFS rate at 3 and 5 years was 92 and 72 %, respectively. The 5-year survival rate after FSRT was 90 %. Also, they did not observe secondary malignancies. Furthermore, compared to conventional techniques, FSRT has the potential of sparing the pituitary gland in chiasmatic lesions. However, radiotherapy must be employed with caution as it increases the risk of having neurocognitive sequelae [31, 32], endocrine impairment [33], late vascular effects like Moya Moya syndrome (especially in NF-1) [34] and second malignancies (reported relative risk of 3.04 for NF-1 patients) [10]. Hence, a longer follow-up is required. In summary, radiotherapy is indicated in children >5 years of age who have significant visual or neurological impairment at presentation, who have clinical or radiological progression while on close observation or <5 years of age who progress on chemotherapy.

4. *Surgical excision* Only if there is cosmetically unacceptable proptosis, definite radiologically documented tumour enlargement or extension (not involving the optic chiasm), or a combination of these, should surgical excision of the lesion be considered [3]. In the presence of good vision, surgery carries the risk of vision loss.

Either an orbital approach or a craniotomy may be performed to excise the tumour. However, with the advent of advanced radiotherapy delivery techniques, which are safer and efficient, surgical intervention is not the treatment of choice.

Malignant optic nerve glioma

Optic nerve gliomas are usually histologically benign and have a fairly predictable course as discussed above. However, rarely malignant astrocytomas that involve the anterior visual system are known to occur. These malignant tumours are known to have a rapid clinical course, characterized by progressive visual loss, neurologic deficits and, eventually, death. The age of presentation varies from the second to the eighth decade, and there is no specific sex predilection.

Clinical features and diagnosis

The clinical features depend on the site of the tumour. Patients with tumours in the proximal part of the optic nerve present with unilateral blurring of vision. Posterior pole haemorrhages—resembling an ischaemic CRVO—and neovascular glaucoma may develop. This does not remain, however, a monocular disease. Within 5–6 weeks, both eyes are affected, leading to completely blindness. Hypothalamic dysfunction, hemiparesis, and other neurologic deficits develop in the latter stages of the disease, and death usually occurs in less than 1 year [3, 37]. Because of the acute visual loss, it may be confused with optic neuritis or anterior ischaemic optic neuropathy [38]. In contrast to ischaemic disease, marked enhancement of the optic nerve is seen on MRI. In the early stages of the disease, MR imaging with gadolinium demonstrates slight enlargement of the anterior optic pathway on postcontrast imaging, simulating optic neuritis and sarcoid. In contrast, nonarteritic ischaemic disease does not enhance. With tumour growth, features are similar to other aggressive malignant gliomas [15].

Patients with tumours in the distal portion of the optic nerve present with progressive unilateral visual loss, neurologic symptoms and death; however, the visual loss in these patients is associated with a normal-appearing optic disc that eventually becomes pale [39].

The histopathology of this tumour is completely different from that of the typical optic nerve glioma, being characterized by extreme cellular pleomorphism, nuclear hyperchromaticity and scattered mitoses.

Treatment

No therapy seems to be able to stop the tumour; radiation is only palliative. Short-term successes have been seen with a combination of chemotherapy and radiation.

Conclusion

Diagnosis of optic nerve gliomas is based on clinical presentation and imaging. The ability to recognize systemic features of NF-1 is important in early diagnosis of optic nerve gliomas. Most tumours present with progressive visual loss and variable proptosis. Neuroimaging helps in diagnostic dilemmas such as differentiation between meningiomas and gliomas, and diagnosing infiltrative optic neuropathies such as leukaemia or lymphoma [40]. The visual outcome and management differ depending upon on the nature of the tumour. The treatment of optic nerve glioma has undergone a paradigm shift, and ophthalmologists must be aware of the signs and symptoms and the management options available. Management of a case of optic nerve glioma requires a team effort among the ophthalmologist, radiologist and oncologist as not only diagnosis but also subsequent treatment and follow-up involves all the three clinicians.

Acknowledgments We would like to acknowledge the contribution of Sumedh S Hoskote, MD; Mayo Clinic, Rochester, MN for the assistance provided and Veena Olma Noronha, MD; VRR Scans, Chennai, India for contributing the radiological images.

Conflict of interest None.

References

1. Wilhelm H (2009) Primary optic nerve tumours. *Curr Opin Neurol* 22(1):11–18
2. Dutton JJ (1994) Gliomas of the anterior visual pathway. *Surv Ophthalmol* 38:427–452
3. Miller NR (2004) Primary tumours of the optic nerve and its sheath. *Eye (Lond)* 18(11):1026–1037
4. Cummings TJ, Provenzale JM, Hunter SB, Friedman AM, Klintworth GK, Bigner SH et al (2000) Gliomas of the optic nerve: histological, immunohistochemical (MIB-1 and p53), and MRI analysis. *Acta Neuropathol* 99:563–570
5. Sharma A, Mohan K, Saini JS (1990) Haemorrhagic changes in pilocytic astrocytoma of the optic nerve. *Orbit* 9:29–33
6. Shapely J, Danesh-Meyer HV, Kaye AH (2011) Diagnosis and management of optic nerve glioma. *J Clin Neurosci* 18(12):1585–1591
7. Listerneck R, Ferner RE, Liu GT et al (2007) Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. *Ann Neurol* 61:189–198
8. Czyzyk E, Józwiak S, Roszkowski M et al (2003) Optic pathway gliomas in children with and without neurofibromatosis 1. *J Child Neurol* 18:471–478
9. Grill J, Laithier V, Rodriguez D et al (2000) When do children with optic pathway tumours need treatment? An oncological perspective in 106 patients treated in a single centre. *Eur J Pediatr* 159:692–696
10. Balcer LJ, Liu GT, Heller G et al (2001) Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging. *Am J Ophthalmol* 131:442–445
11. Dutton JJ (1991) Optic nerve gliomas and meningiomas. *Neurol Clin* 9:163–177
12. Chung EM, Specht CS, Schroeder JW (2007) From the archives of the AFIP: pediatric orbit tumors and tumorlike lesions: neuroepithelial lesions of the ocular globe and optic nerve. *Radiographics* 27(4):1159–1186
13. Becker M, Masterson K, Delavelle J, Viallon M, Vargas MI, Becker CD (2010) Imaging of the optic nerve. *Eur J Radiol* 74(2):299–313
14. Barkovich AJ (2005) *Pediatric neuroimaging*, 4th edn. Lippincott Williams & Wilkins, Philadelphia
15. Weber AL, Caruso P, Sabates NR (2005) The optic nerve: radiologic, clinical, and pathologic evaluation. *Neuroimaging Clin N Am* 15(1):175–201
16. Bianchi-Marzoli S, Brancato R (1994) Tumors of the optic nerve and chiasm. *Curr Opin Ophthalmol* 5:11–17
17. Silva MM, Goldman S, Keating G et al (2000) Optic pathway hypothalamic gliomas in children under 3 years of age: the role of chemotherapy. *Pediatr Neurosurg* 33:151–158
18. Packer RJ, Ater J, Allen J et al (1997) Carboplatin and vincristine for children with newly diagnosed progressive low-grade gliomas. *J Neurosurg* 86:747–754
19. Packer RJ, Lange B, Ater J et al (1993) Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. *J Clin Oncol* 11:850–856
20. Lancaster DL, Hoddes JA, Michalski A et al (2003) Tolerance of nitrosourea-based multiagent chemotherapy regime for low-grade pediatric gliomas. *J Neuro-Oncol* 63:289–294
21. Taveras JM, Mount LA, Wood EH (1956) The value of radiation therapy in the management of glioma of the optic nerves and chiasm. *Radiology* 66:518–528
22. Montgomery AB, Griffin T, Parker RG et al (1977) Optic nerve glioma: the role of radiation therapy. *Cancer* 40:2079–2080

23. Dororetz DE, Blitzer PH, Wang CC et al (1980) Management of glioma of the optic nerve and/or chiasm: an analysis of 20 cases. *Cancer* 45:1467–1471
24. Tao ML, Barnes PD, Billett AL et al (1997) Childhood optic chiasm gliomas: radiographic response following radiotherapy and long-term clinical outcome. *Int J Radiat Oncol Biol Phys* 39(3):579–587
25. Jenkin D, Angyalfi S, Becker L et al (1993) Optic glioma in children: surveillance, resection, or irradiation? *Int J Radiat Oncol Biol Phys* 25(2):215–225
26. Pierce SM, Barnes PD, Loeffler JS et al (1990) Definitive radiation therapy in the management of symptomatic patients with optic glioma. Survival and long-term effects. *Cancer* 65(1):45–52
27. Kovalic JJ, Grigsby PW, Shepard MJ et al (1990) Radiation therapy for gliomas of the optic nerve and chiasm. *Int J Radiat Oncol Biol Phys* 18(4):927–932
28. Cappelli C, Grill J, Raquin M et al (1998) Long-term follow up of 69 patients treated for optic pathway tumours before the chemotherapy era. *Arch Dis Child* 79(4):334–338
29. Shrieve DC, Kooy HM, Tarbell NJ, Loeffler JS (1999) Fractionated stereotactic radiotherapy. In: Alexander E, Maciunas RJ (eds) *Advanced neurosurgical navigation*. Thieme Medical, Stuttgart, pp 451–454
30. Combs SE, Schulz-Ertner D, Moschos D et al (2005) Fractionated stereotactic radiotherapy of optic pathway gliomas: tolerance and long-term outcome. *Int J Radiat Oncol Biol Phys* 62(3):814–819
31. Lacaze E, Kieffer V, Streri A et al (2003) Neuropsychological outcome in children with optic pathway tumours when first-line treatment is chemotherapy. *Br J Cancer* 89(11):2038–2044
32. Chadderton RD, West CG, Schuller S et al (1995) Radiotherapy in the treatment of low-grade astrocytomas. II. The physical and cognitive sequelae. *Childs Nerv Syst* 11(8):443–448 (erratum in: *Childs Nerv Syst* 1995 Dec; 11(12):715)
33. Brauner R, Malandry F, Rappaport R et al (1990) Growth and endocrine disorders in optic glioma. *Eur J Pediatr* 149(12):825–828
34. Kestle JR, Hoffman HJ, Mock AR et al (1993) Moyamoya phenomenon after radiation for optic glioma. *J Neurosurg* 79(1):32–35
35. Kortmann R-D, Timmermann B, Taylor RE et al (2003) Current and future strategies in radiotherapy of childhood low-grade glioma of the brain. Part I: treatment modalities of radiation therapy. *Strahlenther Onkol* 179:509–520
36. Fouladi M, Wallace D, Langston JW et al (2003) Survival and functional outcome of children with hypothalamic/chiasmatic tumors. *Cancer* 97:1084–1092
37. Spoor TC, Kennerdell JS, Martinez Z, Zorub D (1980) Malignant gliomas of the optic nerve pathways. *Am J Ophthalmol* 89:284–292
38. Danesh-Meyer HV, Savino PJ, Bilyk JR, Sergott RC (2005) Aggressive glioma of adulthood simulating ischemic optic neuropathy. *Arch Ophthalmol* 123:694–700
39. Brodovsky S, ten Hove MW, Pinkerton RM, Ludwin SK, Smith RM (1997) An enhancing optic nerve lesion: malignant glioma of adulthood. *Can J Ophthalmol* 32:409–413
40. Gandhi RA, Nair AG (2011) Role of imaging in the management of neuro-ophthalmic disorders. *Indian J Ophthalmol* 59(2):111–116